Amneal Pharmaceuticals (NASDAQ:AMRX) Trading 6.9% Higher - Here's What Happened

Key Points

• Amneal Pharmaceuticals shares rose 6.9% to approximately $17.80 in Wednesday trading, although volume was about 80% below the stock’s average daily level.
• Analyst sentiment remains favorable: eight analysts rate the stock a Buy, one rates it Hold, and the consensus price target is $19.57. Recent targets include $22 from JPMorgan, $23 from Leerink Partners, and $25 from UBS.
• Amneal exceeded quarterly earnings expectations, reporting $0.30 in EPS versus the $0.24 consensus estimate on $796.2 million in revenue. However, insiders sold 413,016 shares worth approximately $7.2 million during the last quarter.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report)'s share price traded up 6.9% during trading on Wednesday . The stock traded as high as $17.46 and last traded at $17.7980. 422,800 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 2,086,597 shares. The stock had previously closed at $16.65.

Analyst Ratings Changes

A number of analysts recently commented on the stock. JPMorgan Chase & Co. reiterated an "overweight" rating and issued a $22.00 target price on shares of Amneal Pharmaceuticals in a research note on Wednesday, August 26th. Weiss Ratings raised shares of Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 26th. UBS Group lifted their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Wall Street Zen raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday, July 12th. Finally, Leerink Partners began coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $23.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $19.57.

Amneal Pharmaceuticals Price Performance

The firm has a market capitalization of $5.67 billion, a PE ratio of 36.32 and a beta of 1.24. The firm's fifty day moving average price is $17.76 and its 200 day moving average price is $15.08. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current year.

Insider Activity

In other news, Director John Kiely sold 50,000 shares of the business's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the transaction, the director owned 210,252 shares of the company's stock, valued at $3,708,845.28. The trade was a 19.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the company's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president owned 253,390 shares in the company, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 413,016 shares of company stock valued at $7,216,567 in the last quarter. 17.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC increased its position in shares of Amneal Pharmaceuticals by 39.1% in the second quarter. Tidal Investments LLC now owns 31,723 shares of the company's stock valued at $549,000 after buying an additional 8,914 shares in the last quarter. WINTON GROUP Ltd lifted its position in shares of Amneal Pharmaceuticals by 21.3% during the 2nd quarter. WINTON GROUP Ltd now owns 144,816 shares of the company's stock valued at $2,507,000 after buying an additional 25,435 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at $139,000. Arizona State Retirement System grew its stake in Amneal Pharmaceuticals by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 44,011 shares of the company's stock valued at $762,000 after acquiring an additional 837 shares during the period. Finally, Allianz Asset Management GmbH purchased a new stake in Amneal Pharmaceuticals in the 2nd quarter worth $225,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.